MedPath
FDA Approval

Triamterene and Hydrochlorothiazide

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Effective Date
October 22, 2019
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Triamterene(37.5 mg in 1 1)
Hydrochlorothiazide(25 mg in 1 1)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Denton Pharma, Inc. DBA Northwind Pharmaceuticals

Denton Pharma, Inc. DBA Northwind Pharmaceuticals

Denton Pharma, Inc. DBA Northwind Pharmaceuticals

080355546

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Triamterene and Hydrochlorothiazide

Product Details

NDC Product Code
70934-143
Application Number
ANDA071251
Marketing Category
ANDA (C73584)
Route of Administration
ORAL
Effective Date
October 22, 2019
FD&C BLUE NO. 1Inactive
Code: H3R47K3TBDClass: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5XClass: IACT
CELLULOSE, MICROCRYSTALLINEInactive
Code: OP1R32D61UClass: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30Class: IACT
SODIUM STARCH GLYCOLATE TYPE A POTATOInactive
Code: 5856J3G2A2Class: IACT
Code: WS821Z52LQClass: ACTIBQuantity: 37.5 mg in 1 1
D&C YELLOW NO. 10Inactive
Code: 35SW5USQ3GClass: IACT
Code: 0J48LPH2THClass: ACTIBQuantity: 25 mg in 1 1
© Copyright 2025. All Rights Reserved by MedPath
Triamterene and Hydrochlorothiazide - FDA Approval | MedPath